- Text: FOMC Minutes
- The Duplicitous Sheila Bair
- Bernanke: Rate Cut Possible to Cure 'Historic' Slump
- Pros Ands Cons For A Rate Cut
- Fed's Moves Will Solve 'Bear of a Problem': Stern
- Russia Gives Banks Extra $36 Billion to Fight Crisis
- Ads That Soothe When Banks Are Failing
- How Can You Help Mend a Broken Market?
- Bonds Cut Losses as Bernanke Hints at Rate Cuts
- Stock Picker: The Real Danger is Inflation!
- Stop Trading!: Sun Going Down on Solar?
- How To Fix Foreclosures
- Write My Blog Contest--Your Chance To Blog Right Here!
- Farrell: Market In A Bottoming Process
- Financial Plays in a Volatile Market
- Brooks Shoes Offers Something "Extra" For Upcoming Marathon
- See What People Are Saying About... Fed's Historic Move
- Crescenzi: Good News from the Fed's Auctions
Text Size 
A drug made by Genentech [DNA
Loading...
()
] received federal approval on Friday to treat breast cancer, a decision that could represent a major shift in standards for assessing the effectiveness of cancer medicines.
Going against the recommendation of its advisory panel, the Food and Drug Administration cleared Genentech's Avastin, which is already approved for treating lung and colon cancer, based on findings that it slowed tumor growth.
The agency has traditionally approved drugs for late-stage cancer if they extended, or improved the quality of, patients' lives. Avastin showed neither, according to Genentech's application.
More on Avastin - |
Wall Street analysts believe FDA's Avastin decision opens the door for other cancer drugs to be approved for their tumor-shrinking capabilities — a trend that worries some health experts.
Print
Email
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes